ReviewNew microbes and new infections2026
Maternal respiratory syncytial virus vaccination for infant protection: updated systematic review and meta-analysis of efficacy, effectiveness, and safety.
Review in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is a major cause of severe illness in infants and young children. Methods: We updated this systematic review to explore the efficacy, effectiveness and safety of authorised maternal RSV prefusion F (RSVpreF) vaccine for infant protection. We searched MEDLINE, Cochrane Library/Central, Embase and grey literature from 2000 to June 2025. We included randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs). Results: Meta-analyses of RCTs showed high certainty of evidence that maternal RSVpreF vaccine lowered medically attended RSV-related lower respiratory tract infections (RSV-LRTI) with vaccine efficacy of 68% (relative risk (RR) 0.32; 95% confidence interval (CI) 0.13 to 0.77, 2 trials; 7656 participants), severe RSV-LRTI with a vaccine efficacy of 84% (RR 0.16; 95% CI 0.07 to 0.36, 2 trials; 7656 participants) and RSV-related hospitalisations with a vaccine efficacy of 70% (RR 0.30; 95% CI 0.15 to 0.61, 1 trial; 7148 participants) in infants. Within the limited evidence base available, there may be little to no difference in RSV-related mortality, all-cause mortality, vaccine-related serious adverse events, and intensive care admission. Requirements for invasive ventilation and duration of hospitalisation due to RSV disease were not reported by any trials. NRSIs suggested effectiveness of 72% (RR 0.28; 95% CI: 0.17 to 0.46, 3 NRSIs; 1229 participants) against hospitalisation, but certainty was very low. Interpretation: Maternal RSVpreF vaccination reduced medically attended and severe RSV-LRTI and RSV-related hospitalisation in infants. No safety signals were identified. Further research is required to clarify the long-term effectiveness of the authorised vaccine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.